S&P 5007,666.60▲0.5% Nasdaq26,217.83▲0.5% Dow53,061.95▲0.6% Russell 2K2,953.17▲1.1% 10-Yr4.80%+0bp VIX15.20−1.14 WTI$90.70▲0.5% Gold$4,431.70▲1.9% EUR/USD1.159▼0.1% BTC$79,153▼1.5% Nikkei66,215▼0.1%
At close · Thu, Sep 3, 2026
Daily Market Updates.

US Markets

Home›US Markets›M&A & Deals›Tempus AI targets the market for personalized cancer t…

Tempus AI targets the market for personalized cancer therapies

Reported · Written up by our desk · M&A & Deals

WSJ Markets reports that Tempus AI is positioning itself to capture a portion of the personalized cancer therapy business being developed by Moderna and Merck.

The outlet says Tempus’s strategy centers on Personalis, which would play a key role in the race to build the infrastructure tied to this therapeutic pipeline.

According to WSJ Markets, the opportunity is framed as a “picks and shovels” type of play, reflecting expected demand around personalized cancer treatment development and associated tools.

← Newer storyJobs data could sway a shaky bond market

More like this

US MarketsJaguar Land Rover to cut 4,000 jobs over two years
US MarketsGrindr to pay £26m to settle UK privacy lawsuit over HIV data sharing
US MarketsTechnipFMC lands more offshore Angola subsea equipment work
US MarketsNvidia agrees to buy Hugging Face in $12.9bn deal
US MarketsBoeing flags $8.4B Spirit acquisition liabilities after closing

Sources

WSJ MarketsThe Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.